ADAP 4Q24 Earnings: EPS Miss on 1x Restructuring/Impairment Costs Potential Capital Raise Adds Risk to the Story
Key 4Q24 takeaways include: 1) Tecelra launch ahead of expectations based on the number of patients apheresed thus far and ATCs up and running,...
209 Views
ADAP: 4Q24 Business Update
Zacks Small-Cap Research Note for Adaptimmune Therapeutics plc (ADAP)
254 Views
Biopharma Week in Review
We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&A.
167 Views
ADAP 2Q24 Earnings: Tecelra FDA Approval + Capital Reload
Key 2Q24 takeaways include: 1) recent FDA approval of Tecelra (afami-cel) triggers immediate onboarding of Authorized Treatment Centers (ATCs),...
214 Views
ADAP: Initiating Coverage of Leading T-Cell Therapy Company
Adaptimmune Therapeutics plc (NASDAQ: ADAP) is a biopharmaceutical company focused on designing, developing, and delivering innovative cell...
235 Views
No more insights